The Fitzgerald protocol unpacked: what the men’s epigenetic RCT actually involved
Earlier in this series, we looked at epigenetic age — the idea that your biological age, as measured by DNA methylation patterns, can run ahead of or behind your chronological age, and that this gap is meaningfully associated with cancer risk. We also noted that a landmark 2021 randomised controlled trial demonstrated that a specific diet and lifestyle programme could measurably shift biological age in a favourable direction.
That trial is the Fitzgerald protocol. This post goes inside it — what the programme actually consisted of, what the trial found, the 2024 correction that refined the headline figure, and what it means for women in their perimenopausal decade who want to act on the epigenetic evidence.
The trial: design and participants
The Fitzgerald et al. 2021 study, published in the journal Aging, was an eight-week randomised controlled trial enrolling 43 healthy men aged 50 to 72. Participants were randomised to either the diet and lifestyle intervention or a waitlist control group. Biological age was assessed using the Horvath epigenetic clock — one of the most well-validated DNA methylation-based biological age measures — from blood samples taken at baseline and at the end of the eight weeks.
It is worth being transparent about the limitations upfront: 43 participants, eight weeks, men only. This is a pilot trial. What makes it notable is the consistency of the directional finding, the rigour of the biological age measurement methodology, and the fact that the protocol is practically specified — the intervention is not a vague “eat better and exercise” instruction, but a detailed multimodal programme.
What the programme involved
The intervention comprised five components, each targeting a different aspect of the biological ageing and methylation pathway.
Diet. A largely plant-rich dietary pattern with specific emphases: abundant leafy greens (two cups per day of mixed greens including kale, spinach, rocket, and chard), cruciferous vegetables, colourful vegetables, and beetroot. Seeds — specifically pumpkin seeds — were included daily for their zinc content. Animal protein was permitted but limited, with an emphasis on liver (once weekly, for its exceptionally high folate, B12, and choline content), eggs, and fish. The dietary pattern was designed to support one-carbon metabolism — the biochemical cycle that provides methyl groups for DNA methylation — through food-first delivery of key methyl-donor nutrients: folate, B12, choline, betaine, and methionine.
Methylation-support supplements. In addition to the dietary methyl donors, participants received a supplement stack including methylfolate (as 5-MTHF), methylcobalamin (B12), vitamin D3, omega-3 fatty acids, and a fruit and vegetable powder. These supplements were designed as an insurance layer on top of the dietary pattern — ensuring sufficiency of nutrients known to support DNA methylation fidelity.
Exercise. At least 30 minutes of moderate-to-vigorous aerobic exercise at least five days per week — a structured, consistent aerobic exercise prescription with firm compliance requirements.
Sleep. Seven hours minimum per night, with guidance on sleep hygiene including consistent bed and wake times and pre-sleep wind-down practices. Sleep is now recognised as a significant regulator of epigenetic maintenance processes.
Stress management. Twice-daily breathing exercises using a specific diaphragmatic technique — each session lasting approximately ten minutes — designed to reduce HPA axis activation and cortisol output, both of which impair DNA methylation enzyme activity.
What the trial found
At eight weeks, the intervention group showed a mean reduction in biological age of 3.23 years compared to the control group, as measured by the Horvath clock. In 2024, a correction was published clarifying the statistical analysis. The corrected figure remains in the same direction and of similar magnitude — the core finding holds that the intervention group showed meaningfully lower biological age at eight weeks compared to controls. Readers should reference the corrected paper (DOI: 10.18632/aging.205700) for the precise updated figure.
An eight-week dietary and lifestyle intervention producing a measurable shift in epigenetic age is biologically plausible — DNA methylation patterns are dynamic and responsive to metabolic inputs — but the durability of the effect beyond the intervention period has not been established in this trial.
The women’s case series
A 2023 follow-up paper by Fitzgerald et al., also published in Aging, applied a similar protocol to six women. This was not a randomised controlled trial — it was a case series, which is a lower level of evidence. The findings were directionally consistent with the men’s RCT, but with only six participants, no control group, and different baseline characteristics, the women’s data is best described as preliminary signal, not confirmation.
For women specifically, this matters: the men’s RCT cannot be assumed to generalise directly, given differences in hormonal context, baseline methylation patterns, and the additional epigenetic disruption associated with the perimenopause. A properly powered women’s RCT has not yet been conducted.
What the protocol targets — and why
The Fitzgerald protocol is built around one-carbon metabolism — the biochemical cycle that generates S-adenosylmethionine (SAM), the universal methyl donor used by DNA methyltransferase enzymes to place methyl groups on cytosine residues in DNA. When this cycle is nutrient-sufficient — adequate folate, B12, choline, betaine, and methionine — methylation fidelity is better maintained. When it is depleted, methylation patterns drift in ways associated with ageing and cancer risk.
The dietary choices are not arbitrary. Leafy greens are among the richest food sources of dietary folate. Liver is extraordinarily rich in folate, B12, and choline. Eggs are a primary dietary source of choline. Beetroot contains betaine. Pumpkin seeds provide zinc, a cofactor for DNA methylation enzymes. Each food choice maps to a specific nutrient gap that the protocol is designed to close.
What this means in practice
The protocol is implementable as a dietary pattern, not just a supplement stack. The most distinctive aspect of the Fitzgerald approach is its food-first emphasis. A woman who prioritises daily leafy greens, regular eggs, weekly oily fish, seeds, and abundant colourful vegetables is already covering the majority of the nutritional foundation.
Methylfolate rather than folic acid. The protocol uses 5-MTHF (methylfolate), not synthetic folic acid. This matters for the substantial proportion of the population with MTHFR gene variants that reduce the efficiency of folic acid conversion to the active form. Methylfolate is directly bioavailable and does not require the conversion step.
Sleep and stress are not optional add-ons. The inclusion of sleep and stress management components reflects genuine mechanistic evidence that cortisol dysregulation and sleep deprivation impair DNA methylation maintenance. A diet-only approach, without addressing sleep and stress, may produce smaller effects.
The evidence base is early-stage. The Fitzgerald RCT is a pilot trial of 43 men over eight weeks — a compelling proof-of-concept, not a definitive prescription. The protocol warrants serious attention and is consistent with the broader evidence base on diet, epigenetics, and cancer risk. It should not be presented as proven treatment or prevention for any specific disease.
What the evidence does not show
The trial does not establish that the biological age reduction produced by the protocol translates directly into reduced cancer incidence or improved disease outcomes. These links are biologically plausible, but have not been demonstrated in a follow-up clinical trial.
The optimal duration of the protocol, whether effects persist after stopping, and whether the same results are achievable in women, in older age groups, or in people with existing health conditions remain open questions.
The bottom line
The Fitzgerald protocol is the most precisely specified dietary and lifestyle intervention in the epigenetic ageing literature, and the 2021 men’s RCT is the strongest randomised evidence that such an intervention can shift biological age in a measurable direction over eight weeks. The protocol works through one-carbon metabolism — targeting the nutrient inputs that support DNA methylation fidelity — through food, targeted supplementation, structured exercise, sleep optimisation, and daily stress management. The evidence is early-stage but mechanistically coherent. For women in the perimenopausal decade, it represents one of the most evidence-informed frameworks available for addressing the biological ageing processes most relevant to cancer risk.
Scientific references
- Fitzgerald KN, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomised clinical trial. Aging. 2021. DOI: 10.18632/aging.202913
- Fitzgerald KN, et al. Correction: potential reversal of epigenetic age. Aging. 2024. DOI: 10.18632/aging.205700
- Fitzgerald KN, et al. Epigenetic age reversal in women: a case series. Aging. 2023. DOI: 10.18632/aging.204602
- Dugué PA, et al. Epigenetic clock and cancer risk: a prospective study. International Journal of Cancer. 2017. DOI: 10.1002/ijc.31189
- Chung W, et al. Epigenetic age acceleration and risk of cancer. Epigenetics. 2021. DOI: 10.1080/15592294.2020.1861401
This article is written for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, prevent, or cure any medical condition, including cancer. If you have a cancer diagnosis or are undergoing treatment, please discuss any lifestyle or dietary changes with your oncologist or medical team before making them. The studies cited reflect current research at the time of writing; the field is evolving rapidly and findings may be updated or superseded. Chloe Archard is a nutritional health coach, not a medical doctor.
